HCV Combination Therapy
AssigneeSTELLA ApS
InventorMichael Hodges
Life of this patent
Estimating the term…
Abstract
The present invention relates to the treatment of hepatitis C (HCV) infection by the combination treatment with a miR-122 inhibitor and a HCV NS5A RNA protein inhibitor.
Claims22
A miR-122 inhibitor for use in the treatment of Hepatitis C (HCV) in combination with an HCV NS5A RNA protein inhibitor, and/or optionally ribavirin (or a virally active derivative thereof).
The miR-122 inhibitor according to claim 1 or 2, wherein the miR-122 inhibitor is an oligomer which consists or comprises the formula:
- 5′-mCsocsAsotstsGsoTsocsasmCsoasmCsotsmCsomCo-3′
- wherein;
- a lowercase letter identifies a DNA unit, and an upper case letter identifies a LNA unit, mC identifies a 5-methylcytosine LNA, subscript s identifies a phosphorothioate internucleoside linkage, and wherein LNA units are beta-D-oxy, as identified by a o superscript after LNA residue.
The use of a miR-122 inhibitor for the preparation of a medicament for the treatment of Hepatitis C, wherein said medicament is for use in combination with an HCV NS5A RNA protein inhibitor.
A method for the treatment of hepatitis C (HCV) infection in a subject infected with HCV, said method comprising the steps of administering an effective amount of a miR-122 inhibitor and an effective amount of a HCV NS5A RNA protein inhibitor to the subject infected with HCV.
Dependencies are inferred from the claim text.